<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227822</url>
  </required_header>
  <id_info>
    <org_study_id>STRONG SFA study</org_study_id>
    <secondary_id>NL43610.060.13</secondary_id>
    <nct_id>NCT03227822</nct_id>
  </id_info>
  <brief_title>Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease</brief_title>
  <acronym>STRONG</acronym>
  <official_title>Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the length of lesion seems to be negatively associated with stent patency due to&#xD;
      restenosis, it is thought that the efficacy of treatment in patients with multiple (&gt; 1)&#xD;
      short (focal; &gt; 1 and &lt; 5 cm) SFA lesions can be improved by spot stenting as compared to the&#xD;
      use of one long stent. This study proposes to evaluate the endovascular treatment for&#xD;
      patients with SFA lesions by comparing two strategies for patients with extensive occlusive&#xD;
      SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to include the number of patients&#xD;
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 1, 2015</completion_date>
  <primary_completion_date type="Actual">February 1, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Short spot stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short spot stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long lesion stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long lesion stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Short spot stenting</intervention_name>
    <arm_group_label>Short spot stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Long lesion stenting</intervention_name>
    <arm_group_label>Long lesion stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PAOD (ABI &lt;0.90 and/or a decline of &gt;0.15 after exercise test), Rutherford category 2,&#xD;
             3 or 4&#xD;
&#xD;
          -  Multiple (&gt;1) short (focal; &gt;1 and &lt; 5 cm) significant stenoses (≥ 50%) and/or&#xD;
             occlusions in the superficial femoral artery&#xD;
&#xD;
          -  Eligible for endovascular treatment via short spot stenting and via long lesion&#xD;
             stenting according to international guidelines&#xD;
&#xD;
          -  Unilateral occlusive disease&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with PAOD Rutherford category 5 and 6&#xD;
&#xD;
          -  Impaired inflow due to significant lesions in the arteries proximal to the SFA&#xD;
             intended to treat&#xD;
&#xD;
          -  Bilateral lesions with treatment indication&#xD;
&#xD;
          -  Contra-indication for anticoagulant therapy&#xD;
&#xD;
          -  Renal insufficiency (MDRD &lt; 50 ml/min)&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Known contrast allergy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable to complete a questionnaire in the home language&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Marc van Sambeek</investigator_full_name>
    <investigator_title>MD, PhD, vascular surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

